J
Joost Rothbarth
Researcher at Erasmus University Rotterdam
Publications - 51
Citations - 1162
Joost Rothbarth is an academic researcher from Erasmus University Rotterdam. The author has contributed to research in topics: Medicine & Survival rate. The author has an hindex of 16, co-authored 41 publications receiving 935 citations. Previous affiliations of Joost Rothbarth include Malmö University & Leiden University Medical Center.
Papers
More filters
Journal ArticleDOI
What is the impact of fecal incontinence on quality of life
Joost Rothbarth,Willem A. Bemelman,Wilhelmus J. H. J. Meijerink,Anne M. Stiggelbout,Aeilko H. Zwinderman,Marianne E. Buyze-Westerweel,Johannes B. V. M. Delemarre +6 more
TL;DR: A Wexner score of 9 or higher indicates a significant impairment of quality of life and can therefore be used in decision making in patients with anterior sphincter repair for fecal incontinence.
Journal ArticleDOI
MRI versus mammography for breast cancer screening in women with familial risk (FaMRIsc): a multicentre, randomised, controlled trial
S. Saadatmand,H Amarens Geuzinge,Emiel J. Th. Rutgers,Ritse M. Mann,Diderick B W de Roy van Zuidewijn,H. M. Zonderland,Rob A. E. M. Tollenaar,Marc B. I. Lobbes,Margreet G. E. M. Ausems,Martijne van 't Riet,Maartje J. Hooning,Ingeborg Mares-Engelberts,Ernest J. T. Luiten,Eveline A.M. Heijnsdijk,Cees Verhoef,Nico Karssemeijer,Jan C. Oosterwijk,Inge-Marie Obdeijn,Harry J. de Koning,Madeleine M. A. Tilanus-Linthorst,Carolien H.M. van Deurzen,Claudette E. Loo,Jelle Wesseling,Margrethe Schlooz-Vries,Suzan van der Meij,Wilma E. Mesker,Kristien Keymeulen,Carolien Contant,Eva V. E. Madsen,Linetta B. Koppert,Joost Rothbarth,Wouter B. Veldhuis,Arjen J Witkamp,Eric Tetteroo,Cécile de Monyé,Mandy M van Rosmalen,Jolanda Remmelzwaal,Huub B W Gort,Roelie Roi-Antonides,Martin N. J. M. Wasser,Edith van Druten +40 more
TL;DR: MRI screening detected cancers at an earlier stage than mammography in women with familial risk of breast cancer, and the lower number of late-stage cancers identified in incident rounds might reduce the use of adjuvant chemotherapy and decrease breast cancer-related mortality.
Journal ArticleDOI
Isolated hepatic perfusion with high-dose melphalan for the treatment of uveal melanoma metastases confined to the liver.
Saidja L Noter,Joost Rothbarth,Milan E. J. Pijl,Jan E.E. Keunen,Henk H. Hartgrink,Fred G.J. Tijl,Peter J. K. Kuppen,Cornelis J.H. van de Velde,Rob A. E. M. Tollenaar +8 more
TL;DR: Although only a small group of patients has been treated and evaluated so far, isolated hepatic perfusion is a treatment option for uveal melanoma metastases confined to the liver which can result in tumour responses and may lead to survival benefits in a selective group of Patients.
Journal ArticleDOI
Isolated hepatic perfusion with high‐dose melphalan for the treatment of colorectal metastasis confined to the liver
Joost Rothbarth,Milan E. J. Pijl,Alexander L. Vahrmeijer,Henk H. Hartgrink,Fred G.J. Tijl,Peter J. K. Kuppen,R.A.E.M. Tollenaar,C.J.H. van de Velde +7 more
TL;DR: A phase II study of isolated hepatic perfusion in patients with colorectal metastases confined to the liver was performed.
Journal ArticleDOI
The use of neo-adjuvant chemotherapy in patients with resectable colorectal liver metastases: Clinical risk score as possible discriminator.
Ninos Ayez,E.P. van der Stok,Dirk J. Grünhagen,Joost Rothbarth,E. van Meerten,Alexander M.M. Eggermont,Cees Verhoef +6 more
TL;DR: In this series, patients with a high CRS benefit from neo-adjuvant CTx in patients with resectable CRLM, and in customers with a low risk profile, neo- adjuvantCTx might not be beneficial.